ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

September 14, 2021

On September 9, the U.S. Department of Health Human Services (HHS) released a report titled, Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy. The report comes following president Biden’s July 2021 Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), which directed HHS to publish a report presenting principles of prescription drug pricing reform.

September 14, 2021

The Association for Clinical Oncology (ASCO) commented on provisions in the 2022 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule that would impact cancer care for Medicare beneficiaries. The letter also offers perspective on CMS’ four-stage plan to transition CMS’ quality measurement enterprise to being fully digital by 2025 and how the agency can improve data collection and measurement to help advance health equity in the Medicare program.

September 14, 2021

On September 9, 2021, the Centers for Medicare & Medicaid Services posted new information on reprocessing claims for outpatient clinic visit services provided at excepted off-campus provider-based departments.

September 14, 2021

On September 10, 2021, the Administration announced that the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), is making $25.5 billion in new funding available for health care providers affected by the COVID-19 pandemic.

September 14, 2021

This summer, members of the Association for Clinical Oncology (ASCO) continued to push forward oncology-focused advocacy priorities by meeting with their Member of Congress or congressional staff during the congressional recess, or district work period.

September 13, 2021

The Association for Clinical Oncology (the Association) launched the ASCO Patient-Centered Cancer Care Certification, a new pilot that certifies outpatient oncology group practices and health systems that meet a single set of comprehensive, expert-backed standards for patient-centered care delivery. The pilot is based on recently published oncology medical home standards (OMH) from the American Society of Clinical Oncology (an affiliate of the Association) and the Community Oncology Alliance (COA).

September 2, 2021

The American Society of Clinical Oncology (ASCO) has a list of resources and information to support cancer care providers and patients affected by natural disasters such as Hurricane Ida.

September 1, 2021

On August 31, 2021, the Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM).

August 26, 2021

On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

August 20, 2021

On August 19, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.

August 19, 2021

On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 

August 18, 2021

The latest issue of JCO Oncology Practice is focused on quality in oncology care. The issue includes a diverse set of articles covering a wide range of topics, including value in cancer care, increasing equity in care delivery, implementing quality measures, addressing cost and value, and more. 

August 17, 2021

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO) released an in-depth analysis of the impact the 2022 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules—as well as pending sequestration cuts—could have on cancer care beginning January 1, 2022. 

August 13, 2021

On August 13, 2021, the Food and Drug Administration approved belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

August 13, 2021

The White House is hosting a virtual conversation for health care providers on the COVID-19 vaccination effort. All ASCO members are encouraged to attend.

Pages